Alcon Unveils India’s First Fully Personalized LASIK Treatment with CDSCO Approval

By accounting for the entire optical system rather than just the cornea, this technology enhances surgical accuracy, safety, and overall visual outcomes.

Alcon, a global leader in eye care, has launched Wavelight Plus, India’s first fully personalized LASIK treatment.

The Central Drugs Standard Control Organisation (CDSCO) in India has approved Wavelight Plus, alongside a CE Mark certification and recent approval from the US Food and Drug Administration (FDA).

The company describes this as a significant advancement in precision refractive surgery. Wavelight Plus introduces a new level of customization that enhances visual outcomes while minimizing risk and ensuring predictable results.

Next-Gen LASIK for India

With myopia being the most prevalent refractive error globally, over 30% of the population currently suffers from it, a figure projected to reach nearly 50% by 2050.

In India, refractive errors are rising due to extended screen time, decreased outdoor activity, and changing lifestyles.

Unlike traditional LASIK treatments, Wavelight Plus utilizes Ray Tracing Technology to construct a Digital Eye Twin, an advanced 3D model of a patient’s eye. This enables surgeons to simulate, test, and refine treatment plans before surgery, ensuring higher precision and fully customized vision correction.

According to the company, this technology enhances surgical accuracy, safety, and overall visual outcomes by accounting for the entire optical system rather than just the cornea.

Clinical data from 200 patients who underwent Wavelight Plus LASIK confirm the technology’s superior visual acuity results, which align with Alcon’s clinical studies.

Research findings from Dr Chandra Bala’s study showed that 100% of myopic eyes achieved an uncorrected distance visual acuity (UDVA) of 20/20 at three months, with at least 89% reaching 20/16, and 50% achieving 20/12.5 within the same period.

Since LASIK became widely available in India, the technology has steadily evolved, progressing from keratometry and refraction to corneal tomography and wavefront aberrometry.

Wavelight Plus builds on these advancements, integrating Sightmap diagnostic technology to fine-tune treatment plans before surgery, providing patients with exceptional visual clarity.

Initially introduced in China, Wavelight Plus is now available across multiple European and Asian markets and has recently secured approval in the US.

Alcon’s Future Plans

Alcon also announced the launch of Clareon PanOptix Pro trifocal IOL in a press release. It will be commercially available in the US starting in May for patients undergoing cataract surgery.

The new intraocular lens (IOL) aims to enhance light distribution across the entire visual range, offering 94% light utilization and a 16% increase in optical image contrast between distance and intermediate vision.

This improvement is made possible by Enlighten NXT optical technology, which is designed to optimize clarity and precision.

The company stated in the release that the IOL delivers "the highest reported light utilization of any trifocal IOL—and the lowest light scatter."

Recently, the Central Drugs Standard Control Organization (CDSCO) introduced an online system for small and medium pharmaceutical enterprises (MSMEs) to submit applications for an extension of the Revised Schedule M implementation deadline.

The new system, integrated into the Online National Drugs Licensing System (ONDLS), follows the Health Ministry’s notification granting an extension for compliance with revised Good Manufacturing Practices (GMP).

Stay tuned for more such updates on Digital Health News.